menu
    • menu

    Company profile for Dicerna Pharmaceuticals

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    DicernaTM Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of RNAi-based therapeutics for diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Dicerna is working to improve the lives of people suffering from diseases involving the liver, including rare diseases, viral infectious diseases, chronic live...
    DicernaTM Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of RNAi-based therapeutics for diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Dicerna is working to improve the lives of people suffering from diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. We discover and develop innovative RNA interference (RNAI)-based therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Dicerna PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    33 Hayden Avenue Lexington, MA 02421
    Telephone
    Telephone
    (617) 621-8097
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://dicerna.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/dicerna-pharmaceuticals-inc.
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/DicernaPharma?ref

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novo Nordisk turns RNA attention to cardio disease in new pact
    Novo Nordisk turns RNA attention to cardio disease in new pact

    17 Jul 2023

    // James Waldron FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/novo-nordisk-turns-rna-attention-cardio-disease-eleven-therapeutics-pact

    James Waldron FIERCE BIOTECH
    17 Jul 2023
    Share Share
    Novo Nordisk Completes Acquisition of Dicerna Pharmaceuticals
    Novo Nordisk Completes Acquisition of Dicerna Pharmaceuticals

    28 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211227005121/en

    BUSINESSWIRE
    28 Dec 2021
    Share Share
    HSR Act Waiting Period Expires for Novo Nordisk Tender Offer to Acquire Dicerna
    HSR Act Waiting Period Expires for Novo Nordisk Tender Offer to Acquire Dicerna

    25 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211225005009/en

    BUSINESSWIRE
    25 Dec 2021
    Share Share
    Ampio Pharmaceuticals CEO passes baton to a new board member; & more
    Ampio Pharmaceuticals CEO passes baton to a new board member; & more

    24 Nov 2021

    // Alex Hoffmann ENDPTS

    https://endpts.com/taking-a-leave-of-absence-ampio-pharmaceuticals-ceo-passes-baton-to-a-new-board-member-axel-hoos-cancer-biotech-lands-a-cfo/

    Alex Hoffmann ENDPTS
    24 Nov 2021
    Share Share
    Novo Nordisk bets big on RNAi, paying $3.3B to buy Dicerna
    Novo Nordisk bets big on RNAi, paying $3.3B to buy Dicerna

    19 Nov 2021

    // N.P. Taylor FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/novo-nordisk-bets-big-rnai-paying-3-3b-to-buy-dicerna

    N.P. Taylor FIERCEBIOTECH
    19 Nov 2021
    Share Share
    Novartis weighs Alnylam buy with Roche stake sale cash: report
    Novartis weighs Alnylam buy with Roche stake sale cash: report

    19 Nov 2021

    // Angus Liu FIERCEPHARMA

    https://www.fiercepharma.com/pharma/where-will-novartis-spend-21b-from-roche-stake-sale-alnylam-could-be-one-report

    Angus Liu FIERCEPHARMA
    19 Nov 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search